In a filing, NeuroOne Medical Technologies Corp revealed its Business Development Director Christianson Mark unloaded Company’s shares for reported $5804.0 on Jun 04 ’25. In the deal valued at $0.58 per share,10,000 shares were sold. As a result of this transaction, Christianson Mark now holds 261,491 shares worth roughly $0.17 million.
Then, Christianson Mark sold 8,967 shares, generating $5,586 in total proceeds. Upon selling the shares at $0.62, the Business Development Director now owns 271,491 shares.
Before that, Christianson Mark sold 14 shares. NeuroOne Medical Technologies Corp shares valued at $9 were divested by the Business Development Director at a price of $0.65 per share. As a result of the transaction, Christianson Mark now holds 280,458 shares, worth roughly $0.18 million.
Ladenburg Thalmann initiated its NeuroOne Medical Technologies Corp [NMTC] rating to a Buy in a research note published on May 05, 2025; the price target was $1.45. A number of analysts have revised their coverage, including Craig Hallum’s analysts, who decreased its forecast for the stock in late March from “a Buy” to “a Hold”.
Price Performance Review of NMTC
On Tuesday, NeuroOne Medical Technologies Corp [NASDAQ:NMTC] saw its stock jump 7.55% to $0.65. Over the last five days, the stock has gained 11.84%. NeuroOne Medical Technologies Corp shares have fallen nearly -21.31% since the year began. Nevertheless, the stocks have fallen -31.71% over the past one year. While a 52-week high of $1.39 was reached on 01/24/25, a 52-week low of $0.40 was recorded on 04/09/25.
Levels Of Support And Resistance For NMTC Stock
The 24-hour chart illustrates a support level at 0.5951, which if violated will result in even more drops to 0.5402. On the upside, there is a resistance level at 0.7025. A further resistance level may holdings at 0.7550.
